Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations

2026-02-13 15:07:01 ET

It’s been a rough go for Alnylam Pharmaceuticals ( ALNY ) since October 2025, with the shares down almost 40% from an all-time high. While it is typically clinical failures that hit biotechs hard, Alnylam is in that awkward biopharma adolescence where investors care more and more about the actual financials. To that end, worries about dynamics in the core TTR market and future profitability loom larger than any concerns about the clinical pipeline....

Read the full article on Seeking Alpha

For further details see: